Message :
Required fields
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
2021-04-19 / 08:31
The issuer is solely responsible for the content of this announcement.
= . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
Evotec Launches BeLAB2122 , Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evotec launches beLAB2122 , translating academic innovation from leading German life science region
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 13, 2021
beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY
EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ
BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122
HAMBURG, GERMANY / / April 13, 2021 /
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.